Abstract
Simple SummaryLung cancer is the leading cause of cancer death, worldwide. The low survival rates are mainly due to disease diagnosis in advanced stages, and the lack of effective treatments. In this study, we analyzed molecules known as microRNAs, which regulate the expression of a large proportion of the human genes. microRNAs are involved in processes related to the development and progression of cancer. In lung cancer, many microRNAs can drive disease. This study showed that some microRNAs have aberrant levels in tumor cells of the two most common types of lung cancer: lung adenocarcinoma and squamous cell carcinoma. In addition, we found that one microRNA, named miR-25-3p, had aberrantly increased levels in tumor cells from patients who died of lung cancer. These results are useful to better understand the biology of lung cancer, and can contribute as an additional tool to predict patient outcome/survival.(1) Background: Although the advances in diagnostic and treatment strategies, lung cancer remains the leading cause of cancer-related deaths, worldwide, with survival rates as low as 16% in developed countries. Low survival rates are mainly due to late diagnosis and the lack of effective treatment. Therefore, the identification of novel, clinically useful biomarkers is still needed for patients with advanced disease stage and poor survival. Micro(mi)RNAs are non-coding RNAs and potent regulators of gene expression with a possible role as diagnostic, prognostic and predictive biomarkers in cancer. (2) Methods: We applied global miRNA expression profiling analysis using TaqMan® arrays in paired tumor and normal lung tissues (n = 38) from treatment-naïve patients with lung adenocarcinoma (AD; n = 23) and lung squamous cell carcinoma (SCC; n = 15). miRNA target genes were validated using The Cancer Genome Atlas (TCGA) lung AD (n = 561) and lung SCC (n = 523) RNA-Seq datasets. (3) Results: We identified 33 significantly deregulated miRNAs (fold change, FC ≥ 2.0 and p < 0.05) in tumors relative to normal lung tissues, regardless of tumor histology. Enrichment analysis confirmed that genes targeted by the 33 miRNAs are aberrantly expressed in lung AD and SCC, and modulate known pathways in lung cancer. Additionally, high expression of miR-25-3p was significantly associated (p < 0.05) with poor patient survival, when considering both tumor histologies. (4) Conclusions: miR-25-3p may be a potential prognostic biomarker in non-small cell lung cancer. Genes targeted by miRNAs regulate EGFR and TGFβ signaling, among other known pathways relevant to lung tumorigenesis.
Highlights
Lung cancer is the leading cause of cancer death worldwide
Of the 38 samples included in the study, 23 patients were diagnosed with lung AD and 15 with lung squamous cell carcinoma (SCC)
Patients with lung SCC had an average age of 62 years, with a predominance of males
Summary
Lung cancer is the leading cause of cancer death worldwide. Current incidence data estimates over 2 million new cases/year, with 62% of cases occurring in developed countries, mainly in NorthAmerica and Western countries, and 38% in developing countries [1]. Lung cancer is the leading cause of cancer death worldwide. Current incidence data estimates over 2 million new cases/year, with 62% of cases occurring in developed countries, mainly in North. America and Western countries, and 38% in developing countries [1]. In Brazil, incidence data estimates the occurrence of approximately 30,000 new cases/year [2]. The 5-year survival rate remains low at approximately 19%. The low survival rates are mainly due to late diagnosis, with only 15% of patients diagnosed with localized disease, 22% of patients with lymph node metastasis, 57% with distant metastasis and 6% with an undetermined disease stage [3]. Non-small cell lung cancer (NSCLC) comprises of the majority (85%) of lung cancer cases, with adenocarcinoma (AD) and squamous cell carcinoma (SCC) as the two major histological subtypes
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have